Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Hun Ho Song"'
Autor:
Junghoon Shin, Youngil Koh, Seo Hyun Yoon, Joo‐Youn Cho, Dae‐Young Kim, Kyoo‐Hyung Lee, Hyeong‐Joon Kim, Jae‐Sook Ahn, Yeo‐Kyeoung Kim, Jinny Park, Sang‐Kyun Sohn, Joon Ho Moon, Yoo Jin Lee, Seonghae Yoon, Jeong‐Ok Lee, June‐Won Cheong, Kyoung Ha Kim, Sung‐Hyun Kim, Hoon‐Gu Kim, Hawk Kim, Seung‐Hyun Nam, Young Rok Do, Sang‐Gon Park, Seong Kyu Park, Sung Hwa Bae, Hun Ho Song, Dong‐Yeop Shin, Doyeun Oh, Min Kyoung Kim, Chul Won Jung, Seonyang Park, Inho Kim
Publikováno v:
Cancer Medicine, Vol 7, Iss 5, Pp 1814-1823 (2018)
Abstract Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2
Externí odkaz:
https://doaj.org/article/d3afcb08b0d94b2f8771feee46de40c7
Autor:
Hyunkyung Park, Sungbong Kang, Inho Kim, Sangsoo Kim, Hyeong-Joon Kim, Dong-Yeop Shin, Dae-Young Kim, Kyoo-Hyung Lee, Jae-Sook Ahn, Sang-Kyun Sohn, Jeong-Ok Lee, June-Won Cheong, Kyoung Ha Kim, Hoon-Gu Kim, Hawk Kim, Yoo Jin Lee, Seung-Hyun Nam, Young Rok Do, Sang-Gon Park, Seong Kyu Park, Hun Ho Song, Chul Won Jung, Seonyang Park
Publikováno v:
Leukemia research. 114
Genetic differences may be associated with the response to tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia (CML). In this study, we identified genetic alterations between rapid and slow responders (BCR/ABL1 International Sca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88be9dd6694de836c94731719f673e68
https://pubmed.ncbi.nlm.nih.gov/35101736
https://pubmed.ncbi.nlm.nih.gov/35101736
Autor:
Seong Kyu Park, Inho Kim, Hyun-Kyung Park, Jae-Sook Ahn, Chul Won Jung, Seonyang Park, Sang-Kyun Sohn, Kyoo-Hyung Lee, Jinny Park, June-Won Cheong, Young Rok Do, Jeong Ok Lee, Dong-Yeop Shin, Hun Ho Song, Oh-Hyung Kwon, Sung-Yeoun Lee, Hawk Kim, Hyeong-Joon Kim, Sung Hwa Bae, Kyoung Ha Kim, Doyeun Oh, Hoon-Gu Kim, Sang-Gon Park, Yoo Jin Lee, Dae-Young Kim, Seung-Hyun Nam
Publikováno v:
Leukemia research. 111
Ultra-deep sequencing detects low-frequency genetic mutations with high sensitivity. We used this approach to prospectively examine mutations in the BCR/ABL1 tyrosine kinase from patients with newly diagnosed, chronic-phase chronic myeloid leukemia (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::093e7a1d6651481278179b540fd213cf
https://pubmed.ncbi.nlm.nih.gov/34673444
https://pubmed.ncbi.nlm.nih.gov/34673444
Autor:
Jae Sook Ahn, Young Rok Do, Jinny Park, Joo Youn Cho, Kyoung Ha Kim, Kyoo Hyung Lee, Min Kyoung Kim, Seong Kyu Park, Inho Kim, Hawk Kim, Seo Hyun Yoon, Hun Ho Song, Sung Hwa Bae, Seonghae Yoon, Doyeun Oh, Joon Ho Moon, Dae-Young Kim, Hoon Gu Kim, Sang Kyun Sohn, Chul Won Jung, Sung-Hyun Kim, Yeo Kyeoung Kim, Junghoon Shin, Yoo Jin Lee, Seonyang Park, Sang Gon Park, Hyeong Joon Kim, Seung Hyun Nam, Dong Yeop Shin, Youngil Koh, Jeong Ok Lee, June-Won Cheong
Publikováno v:
Cancer Medicine
Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2‐year e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88c08c0f8ff83e207e736aff83c7d01f
http://europepmc.org/articles/PMC5943463
http://europepmc.org/articles/PMC5943463
Autor:
Hyeong Su Kim, Hyo Jung Kim, Hun Ho Song, Jung Hye Kwon, Jung Han Kim, Joo Young Jung, Hee Sung Hwang, Ju Seok Kim, Young Kyung Lee, Dae Ro Choi, Geun Doo Jang, Hwa Jung Kim, Soo Kee Min, Dae Young Zang, Ho Young Kim
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Bone marrow biopsy is a standard method for the evaluation of bone marrow infiltration by lymphoma; however, it is an invasive and painful procedure. Fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET-CT) is a noni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42c22cc56efd6620ecf5f3e8490152aa
https://doi.org/10.4143/crt.2014.091
https://doi.org/10.4143/crt.2014.091
Autor:
Geundoo Jang1, Hun Ho Song1, Keon Uk Park2, Hyeong Su Kim3 hemonc@hallym.or.kr, Dae Ro Choi4, Jung Hye Kwon1, Ho Young Kim5, Boram Han5, Jung Han Kim3, Joo Young Jung6, Hyo Jung Kim5, Dae Young Zang5
Publikováno v:
Cancer Research & Treatment. Sep2013, Vol. 45 Issue 3, p172-177. 6p.
Autor:
Jung Hye Kwon, Boram Han, Jung Han Kim, Hun Ho Song, Ho Young Kim, Dae Young Zang, Joo Young Jung, Keon Uk Park, Hyo Jung Kim, Dae Ro Choi, Hyeong Su Kim, Geundoo Jang
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
PURPOSE Combination therapy with aprepitant, serotonin receptor antagonist, and steroids improves the complete response rate of both acute and delayed chemotherapy-induced nausea and vomiting (CINV). However, it is not known whether ramosetron is sui
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0c900ff879ec7c09f887b1540bb2290
http://europepmc.org/articles/PMC3804728
http://europepmc.org/articles/PMC3804728
Autor:
Hun Ho Song, Jae Ho Byun, Jin Seok Ahn, Keun Seok Lee, Young Lee Park, Jung Ae Lee, Dae Young Jang, In Sook Woo, Young Suk Park
Publikováno v:
Cancer research and treatment. 34(6)
Purpose To evaluate the efficacy and safety of ifosfamide, carboplatin and epirubicin (ICE) combination chemotherapy for extensive disease small cell lung cancer (SCLC) patients, who had received no previous chemotherapy, we performed phase II trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf34ddbc5ef31815e6c03bfdbfb0e7a4
https://pubmed.ncbi.nlm.nih.gov/26680897
https://pubmed.ncbi.nlm.nih.gov/26680897
Autor:
Joo Young Jung, Jung Han Kim, Geundoo Jang, Jung Hye Kwon, Ho Young Kim, Dae Ro Choi, Hun Ho Song, Hee-sung Lee, Hyo Jung Kim, Sang Myeon Park, Dae Young Zang, Tae Rim Shin, Hyeong Su Kim, Gyeong-Won Lee
Publikováno v:
Lung Cancer. 70:71-76
Background Although platinum-based doublet chemotherapy is considered as standard of care for patients with advanced non-small cell lung cancer (NSCLC), most of them are eventually supposed to experience disease progression. Pemetrexed, docetaxel, er
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b32c979ae734ba4ec204fecf0c737c1
https://doi.org/10.1016/j.lungcan.2009.12.015
https://doi.org/10.1016/j.lungcan.2009.12.015
Autor:
Joo Young Jung, Young-Iee Park, Jung Hye Kwon, Hyun Chun Shin, Jung Han Kim, Dae Young Zang, Ho Young Kim, Hyeong Su Kim, Hun Ho Song, Hyo Jung Kim, Jung-Ae Lee, Dae Ro Choi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 66:889-897
Docetaxel and cisplatin combination chemotherapy is established first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). We evaluated a weekly schedule of docetaxel and cisplatin for efficacy and tolerability in patients with chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0837696e8c9cab73d8e56d67a2d2fa
https://doi.org/10.1007/s00280-009-1235-y
https://doi.org/10.1007/s00280-009-1235-y